Limbic Predominant Age Related Tdp 43 Encephalopathy (Late) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE) is a recently recognized neurodegenerative condition characterized by TDP-43 protein pathology predominantly affecting the limbic system, particularly in older adults. First described in 2019, LATE represents an underappreciated cause of dementia that often mimics Alzheimer's Disease but has distinct pathological features. [1]
Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a recently recognized neurodegenerative disease characterized by the accumulation of misfolded TDP-43 protein in the limbic system, particularly the amygdala and hippocampus. First formally defined by a consensus working group in 2019, LATE produces a clinical syndrome that closely mimics Alzheimer's disease but has distinct molecular pathology.[2] [3]
LATE is among the most common causes of dementia in older adults, affecting approximately 20–50% of individuals over age 80 at autopsy. The condition frequently co-occurs with Alzheimer's Disease neuropathologic change, and when both pathologies are present, cognitive decline is more severe than with either alone.[1:1] [4]
LATE neuropathologic change (LATE-NC) is remarkably prevalent in the aging brain: [5]
This TDP-43 pathology is shared with ALS and frontotemporal lobar degeneration (FTLD-TDP), but in LATE, the distribution is distinctly limbic-predominant rather than involving motor neurons or frontotemporal cortex.[5:1] [^6]
LATE neuropathologic change follows a stereotypical spatial progression:[2:2] [^7]
| Stage | Region Affected | Description | [^8]
|-------|----------------|-------------| [^9]
| Stage 0 | None | No TDP-43 cytoplasmic inclusions detected | [^10]
| Stage 1 | amygdala | TDP-43 inclusions restricted to the amygdala |
| Stage 2 | hippocampus | Spread to hippocampus and entorhinal cortex |
| Stage 3 | Neocortex | Extension to middle frontal gyrus and additional neocortical regions |
Higher stages correlate with greater cognitive impairment. Stage 1 may be asymptomatic, while stages 2 and 3 are associated with progressive memory loss and clinical dementia.
A frequent companion pathology in LATE is hippocampal sclerosis of aging (HS-Aging), characterized by:
Hippocampal sclerosis is present in approximately 10–25% of LATE cases and is associated with more severe memory impairment.[^6]
LATE-NC frequently co-occurs with other neuropathologies:
Several genetic loci have been replicated as risk factors for LATE-NC:[3:1]
| Gene | Variant | Effect | Notes |
|---|---|---|---|
| TMEM106B | rs1990622 | Risk/protection | Also associated with FTLD-TDP; modulates TDP-43 aggregation |
| GRN | rs5848 | Risk | Encodes progranulin; complete GRN loss causes FTLD; partial loss contributes to LATE |
| [APOE | ε4 allele | Risk | Shared risk factor with Alzheimer's disease |
| SORL1 | Multiple variants | Risk | Also associated with Alzheimer's Disease |
| ABCC9 | rs1914361, rs701478 | Risk | Encodes SUR2 potassium channel subunit; linked to vascular pathology |
| KCNMB2 | Multiple variants | Risk | Encodes potassium channel subunit |
The shared genetic architecture between LATE and FTLD-TDP (via GRN and TMEM106B) and with Alzheimer's disease (via APOE and SORL1) suggests converging biological pathways despite distinct clinical presentations.[^7]
LATE presents as a slowly progressive amnestic dementia syndrome that is clinically indistinguishable from Alzheimer's Disease during life:
| Feature | LATE | Alzheimer's disease |
|---|---|---|
| Typical onset age | >80 years | 60–80 years (late-onset) |
| Core protein | TDP-43 | amyloid-beta and tau] |
| Brain regions | Limbic (amygdala, hippocampus) | Widespread cortical |
| amyloid PET | Negative (pure LATE) | Positive |
| Progression rate | Slower | Moderate to rapid |
| Genetic risk | TMEM106B, GRN, APOE | APOE, APP, PSEN1, PSEN2 |
LATE can only be definitively diagnosed at autopsy through neuropathological examination for TDP-43 inclusions. During life, a clinical diagnosis of "probable LATE" is increasingly feasible using a combination of approaches.[^8]
In 2025, the first clinical diagnostic criteria for LATE were published:[^8]
There are no approved treatments specifically targeting LATE. Current management is supportive:
The recognition of LATE has important implications for Alzheimer's therapeutics:
The study of Limbic Predominant Age Related Tdp 43 Encephalopathy (Late) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.
The role of brain MR and FDG-PET in the diagnosis of neurodegenerative disease. ↩︎ ↩︎ ↩︎
Progression of fiber bundle damage in amnestic Alzheimer's disease and LATE: a 2-year fixel-based study. ↩︎ ↩︎ ↩︎ ↩︎
Elucidation of Molecular Mechanisms of Lipid-Altered Cytotoxicity of TDP-43 Fibrils. ↩︎ ↩︎ ↩︎
TRIM32-UBQLN2-p62 axis promotes TDP-43 inclusion formation and amyloid aggregation through shuttle condensates. ↩︎
TDP-43 pathology is linked to motor neuron loss but is independent of stress granules in vivo. ↩︎ ↩︎